RecruitingNCT07480915

Risk Stratification of MACE in Heart Failure Patients Who Undergoing CABG

Risk Stratification of MACE Based on GDF-15 in Heart Failure Patients Who Undergoing Coronary Artery Bypass Grafting: an Observational Multicenter Prospective Study

Sponsor

Tomsk National Research Medical Center of the Russian Academy of Sciences

Enrollment

160 participants

Start Date

Mar 4, 2026

Study Type

OBSERVATIONAL

Conditions

Heart Failure CABG CAD - Coronary Artery Disease

Summary

PROFILE-HF is a multicenter, observational, prospective study of the clinical course and outcomes of chronic heart failure (HF) and coronary artery disease (CAD) in patients undergoing coronary artery bypass grafting (CABG). The objective of the study is to develop a method for assessing the risk of adverse cardiovascular events in patients with CAD and HF who have undergone CABG, based on preoperative GDF-15 concentrations. The study will have a 12-month follow-up period; one in-person visit is planned at the end of the follow-up period. If it is not possible to visit a doctor in person, information will be collected through telephone contact with the patient or his relative or person caring for the patient.

Eligibility

Plain Language Summary

Simplified for easier understanding

This study is looking at how to better predict which heart failure patients are at highest risk for serious heart complications (such as heart attack or stroke) when they undergo coronary artery bypass graft (CABG) surgery — a procedure that reroutes blood around blocked heart arteries. Better risk prediction could help doctors make safer surgical decisions. **You may be eligible if...** - You have been diagnosed with heart failure - You are scheduled to have coronary artery bypass graft (CABG) surgery **You may NOT be eligible if...** - You have had a recent heart attack or stroke - You have an implanted device (such as a pacemaker) - You need additional heart surgery beyond CABG (e.g., valve repair) - You have severe kidney disease - You have active cancer, certain heart muscle diseases, autoimmune diseases, or active infections Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Cardiology Research Institute, Tomsk National Research Medical Center Russian Academy of Sciences

Tomsk, Tomsk Oblast, Russia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07480915

Related Trials

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288653 locations

Impact of Optimized Pacing Strategies on Clinical and Hemodynamic Outcomes in Heart Failure Patients With Pacemaker

NCT075631531 location

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

NCT06935370638 locations

The Salt Study for Heart Failure

NCT075605921 location

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

NCT06991257135 locations